Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2^nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK.

Ms. Maia Hansen, Chief Operating Officer, and Dr. Sarah Busch, Vice President of Regenerative Medicine, will be participating in talks during Advanced Therapies week in Miami, FL. Ms. Hansen has been invited to chair the session titled, “What Does a Global Supply Chain Look Like for CGT? Defining End-To-End Logistics,” on January 18^th. During this session, Ms. Hansen will also be giving a presentation titled, “The Last Mile to the Patient in Cell Therapy.” Dr. Busch will be giving a presentation on January 20^th titled, “MultiStem Cell Therapy for Neurological Indications.” Each will be speaking in their areas of expertise, attending the conference to collaborate and network with leaders across the advanced therapies industry.

The following are specific details regarding the Athersys presentations during Advanced Therapies Week:

Event:	The Last Mile to the Patient in Cell Therapy
Date:	Wednesday, January 18, 2023
Time:	11:05 AM Eastern Time
Location:	Miami Beach Convention Center, 1901 Convention Ctr Dr, Miami Beach, FL 33139

Event:	MultiStem Cell Therapy for Neurological Indications
Date:	Friday, January 20, 2023
Time:	9:50 AM Eastern Time
Location:	Miami Beach Convention Center, 1901 Convention Ctr Dr, Miami Beach, FL 33139

Please visit https://advancedtherapiesweek.phacilitate.com/ for additional information and registration.

Additionally, from January 30-February 1, Dr. Manal Morsy, Executive Vice President and Head of Global Regulatory Affairs, will be attending and speaking at the 2^nd Allogeneic Cell Therapy Summit Europe. Dr. Morsy will be participating on a panel on January 31^st titled, “Understanding the Regulatory Landscape for Allogeneic Cell Therapy Products to Aid Forward Planning and Goals.” Details on this presentation are as follows. Please visit https://allogeneic-cell-therapies-europe.com/ for additional information and registration.